An observational study in Cognitive Impairment, Hematologic Malignancies and Chemotherapy Effect, sponsored by Assiut University. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cognitive Dysfunction by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Cognitive Dysfunction · Assiut University.
Among the 10 studies in Cognitive Dysfunction by Assiut University, this one is one of 4 that started in 2026, is one of 8 observational ones, and was the 9th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →6 of the 10 studies in Cognitive Dysfunction by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages 16–60 · Healthy volunteers
Assiut University
Ages 50+ · Healthy volunteers
Assiut University
Ages 18–45
Assiut University
Ages 18+
Assiut University
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 120 is below the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 64 across the 2 interventional studies, 80 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Cognitive Dysfunction by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678918Assiut UniversityCognitive Function and Quality of Life in Obstructive Sleep Apnea | 2027-08 |
| NCT07842679Assiut UniversityCognitive Impairment in Older Adults With Hematologic Malignancies | 2027-09-26 |
| NCT07852052Assiut UniversitySleep Architecture, Cognitive Function, and Quality of Life During Early Recovery From Substance Use Disorder | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Cognitive Dysfunction by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.
Cognitive impairment is common among older adults with cancer and may affect treatment adherence and independence. This observational study will include adults aged 65 years or older with confirmed hematologic malignancies who are currently receiving chemotherapy.
Participants will undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) and functional assessment using the Katz Index of Activities of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL).
Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment.
Prevalence of cognitive impairment
Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26.
Time frame: Baseline
Mean MoCA score
Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition)..
Time frame: Baseline
Mean Katz ADL score
Mean Katz Index of Independence in Activities of Daily Living score (range 0-6, higher scores indicate greater independence).
Time frame: Baseline
Mean Lawton IADL score
Mean Lawton Instrumental Activities of Daily Living score (range 0-8, higher scores indicate greater independence)
Time frame: Baseline
Proportion with impaired activities of daily living
Proportion of participants with impaired Katz ADL score.
Time frame: Baseline
Proportion with impaired instrumental activities of daily living
Proportion of participants with impaired Lawton IADL score.
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.